Bone Marrow CD34+ Cells, 300,000 cells, cryopreserved, positively selected
For medium-throughput transfection of cell lines, e.g. K-562, Neuro-2A or RAW246.7, when working with the 4D-Nucleofector® 96-well Unit
For high-throughput transfection of cell lines, e.g. K-562, Neuro-2A or RAW246.7, when working with the 384-well HT Nucleofector® System.
For high-throughput transfection of cell lines, e.g. K-562, Neuro-2A or RAW246.7, when working with the 384-well HT Nucleofector® System.
For medium-throughput transfection of cell lines, e.g. K-562, Neuro-2A or RAW246.7, when working with the 4D-Nucleofector® 96-well Unit
Fixed-volume reaction vessel for the 4D-Nucleofector® LV Unit PRO for research and process development. Use in combination with P3 Nucleofector® Solution LV Sets.
The controlling unit of the 4D-Nucleofector® System is suited to handle various functional units for efficient transfection of hard-to-transfect cell lines and primary cells in different formats.
Flow-through reaction vessel for the 4D-Nucleofector® LV Unit PRO for research and process development. Easily scalable to up to 1 billion cells. Use in combination with P3 Nucleofector® Solution LV Sets and 4D-Nucleofector® LV Reservoirs.
-
References - X-Vivo™Overview of relevant references
-
X-VIVO Reference Guide 2025A curated list of peer-reviewed articles related to X-VIVO RUO media as used for culturing different primary cells and is a resource for potential consumers to find scientific data.
-
Instructions for Use – TheraPEAK® X-VIVO® Cell Culture MediumInstructions for how to use the X-VIVO® Media Series
-
A Novel In Vitro Liver Cell Culture Flow System Allowing Long-Term Metabolism and Hepatotoxicity Studies]Manuscript published in Applied In Vitro Toxicology journal describes improvement of CYP450 phenotype of primary cryopreserved hepatocytes using Quasi Vivo® System
-
TheraPEAK® X-VIVO® Hematopoietic Cell Culture MediumSerum-free, GMP produced medium for cell therapy applications
-
Formulation - Leibovitz Modified Medium (L-15)Composition of L-15 (12-669)
-
A Non-Viral Method for Modifying and Expanding Primary T CellsLearn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.
-
Formulation - Leibovitz Medium (L-15)Components present in L-15 (12-700).
-
Primary Normal Human Cells and MediaIn Vivo Relevance. In Vitro Results. Updated and revised cell content.
-
TechSheet – L-15 Leibovitz MediumHow to use L-15 Medium